Short answer
Akebia Therapeutics, Inc. (AKBA) filed an 8-K current report with the SEC on October 23, 2026 reporting Item 3.01 (Notice of Delisting). Nasdaq deficiency notice: AKBA closed below the $1.00 minimum bid for 30 consecutive business days.
- This filing includes Item 3.01, an item that often signal trouble.
Akebia Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 3.01 · Notice of Delisting
- Nasdaq deficiency notice: AKBA closed below the $1.00 minimum bid for 30 consecutive business days
- No immediate delisting: initial 180-day cure period runs through April 19, 2027
- Compliance requires at least $1.00 closing bid for 10 consecutive business days
- Potential second 180-day period, with reverse stock split a possible remedy
- Failure to cure could trigger delisting proceedings and Nasdaq Hearings Panel appeal риска
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Akebia Therapeutics, Inc. 8-K filings
Get the next AKBA 8-K as it lands
Follow AKBA for push alerts, or ask the research agent what this filing means.